Evenity (Romosozumab) Sleep Architecture Impact

What Romosozumab Does, and Does Not, Say About Sleep on the Label

The FDA-approved prescribing information for romosozumab contains no mention of insomnia, somnolence, or altered sleep staging as expected adverse events [1]. The label's adverse-reaction table from the pooled FRAME and ARCH trial data lists injection-site reactions (occurring in roughly 18% of patients), arthralgia, and headache as the most common complaints, none of which involve polysomnographic endpoints [1].

That absence of labeling is not the same as biological irrelevance. Absence of evidence differs from evidence of absence, particularly when the mechanism of action touches neural pathways that neuroscientists have separately linked to circadian control.

What the ARCH Trial Actually Measured

The ARCH trial enrolled 4,093 postmenopausal women with osteoporosis and at least one prior vertebral fracture, randomizing them to romosozumab 210 mg monthly versus alendronate 70 mg weekly for 12 months, followed by open-label alendronate [2]. At 24 months, romosozumab-to-alendronate reduced new vertebral fractures by 48% compared with alendronate-to-alendronate (6.2% vs. 11.9%, P<0.001) [2]. Sleep quality was not a prespecified secondary endpoint in ARCH, so no polysomnographic or patient-reported sleep data were collected.

The FRAME trial (N=7,180) similarly focused on vertebral and nonvertebral fracture outcomes over 12 months of romosozumab versus placebo, with no sleep-quality instrument in the protocol [3].

Patient-Reported Outcomes and Sleep Signals

FRAME did use the SF-36 health-related quality-of-life instrument, where the vitality and mental health subscales capture fatigue and sleep-related distress indirectly [3]. Published FRAME data showed no statistically significant difference in SF-36 vitality scores between romosozumab and placebo at month 12, suggesting gross fatigue burden was not altered [3]. The SF-36 is not a validated polysomnographic surrogate, so this finding is reassuring but not conclusive.

The Biology: How Sclerostin Inhibition Could Touch Sleep Circuits

Romosozumab binds sclerostin, a glycoprotein encoded by the SOST gene, blocking its inhibitory effect on Wnt/beta-catenin signaling [1]. In bone, this increases osteoblast activity and decreases osteoclast-mediated resorption. Outside bone, Wnt/beta-catenin activity has been detected in neurons of the suprachiasmatic nucleus (SCN), the master pacemaker for circadian rhythms [4].

Wnt Signaling in the Suprachiasmatic Nucleus

A 2014 study in the journal PNAS demonstrated that Wnt3a infusion into SCN tissue ex vivo altered the period length of circadian oscillations by approximately 1.5 hours, mediated through beta-catenin stabilization of the clock gene Rev-erb-alpha [4]. Romosozumab does not cross the blood-brain barrier under normal physiological conditions. Sclerostin expression has been identified in human cerebrospinal fluid at nanomolar concentrations, however, raising the theoretical question of whether peripheral sclerostin inhibition could shift CNS Wnt tone indirectly [5].

This is speculative at present. No clinical trial has measured SCN firing rates or circadian gene expression in patients receiving romosozumab.

Bone-Derived Signals That Modulate Sleep

Osteocalcin, a protein secreted by osteoblasts that romosozumab activates, has received attention as a bone-to-brain signaling molecule. A 2019 Cell Metabolism paper by Khrimian and colleagues reported that osteocalcin crosses the blood-brain barrier and binds brainstem neurons to promote memory consolidation during non-REM sleep in mice [6]. If romosozumab increases osteocalcin secretion, which Phase 2 data suggest it does transiently within the first 3 months of treatment [7], there is a mechanistic pathway, however indirect, by which anabolic bone therapy might influence sleep staging.

The operative word is "might." No human RCT has tested this link directly.

Pain Reduction as a Functional Sleep Benefit

One pragmatic mechanism deserves attention. Severe osteoporosis frequently involves chronic vertebral and peripheral pain that fragments sleep architecture, increasing N1 and N2 light-sleep proportion while suppressing slow-wave sleep [8]. The ARCH trial demonstrated a statistically significant reduction in clinical fracture incidence at 12 months (romosozumab 5.9% vs. Alendronate 6.9%; P = 0.04 for all clinical fractures at 24 months) [2]. Fewer fractures means less acute and chronic pain, which may functionally improve sleep continuity, an indirect benefit not captured by any sleep-specific endpoint in existing trials.

Cardiovascular Warning and Its Potential Sleep Connection

The FDA black-box warning on romosozumab was added following the ARCH trial's finding of a higher rate of serious cardiovascular events in the romosozumab arm compared with alendronate: 2.5% vs. 1.9% within the first 12 months, representing 50 vs. 38 patients experiencing a major adverse cardiovascular event (MACE) [2]. The label now states that romosozumab should not be initiated in patients who have had a MI or stroke within the preceding year [1].

Why This Matters for Sleep Assessment

Obstructive sleep apnea (OSA) independently elevates cardiovascular risk through intermittent hypoxia and sympathetic nervous system activation [9]. A patient with undiagnosed OSA who receives romosozumab carries additive cardiovascular risk. The American Heart Association's 2021 scientific statement on sleep and cardiovascular disease noted that OSA affects approximately 34% of men and 17% of women in the United States general population, with prevalence rising substantially in older postmenopausal women, precisely the demographic targeted by romosozumab [9].

Screening for OSA before initiating romosozumab is not currently recommended in the label, but the overlap in high-risk populations makes a clinical argument for at least a STOP-BANG questionnaire at baseline.

No Direct Cardiovascular-Sleep-Romosozumab Trial Data

No published trial has stratified romosozumab MACE outcomes by baseline sleep-disorder status or polysomnographic findings. This is a gap that future pharmacovigilance studies could address, particularly given that the FDA Adverse Event Reporting System (FAERS) database entries for romosozumab through 2024 do not prominently feature sleep complaints as a signal [10].

What Real-World Pharmacovigilance Shows

The FDA FAERS database contains post-marketing reports for romosozumab since its 2019 approval. Through mid-2024, the primary safety signals in FAERS remain consistent with trial findings: cardiovascular events, osteonecrosis of the jaw (rare, <0.1%), atypical femoral fracture (rare), and hypocalcemia [10]. Sleep disturbance does not appear as a disproportionate reporting ratio signal in publicly available FAERS summaries, which uses the proportional reporting ratio (PRR) methodology with a threshold of PRR >2 and chi-squared >4 [10].

FAERS is subject to substantial underreporting, and sleep complaints are among the most underreported adverse events because patients rarely attribute sleep changes to a once-monthly injectable bone drug.

Injection-Site Reactions and Sleep Disruption

Injection-site reactions occurred in 18.2% of romosozumab patients vs. 5.8% of placebo patients in FRAME [3]. Local pain, erythema, and swelling peaking 24 to 72 hours post-injection could disrupt sleep on injection nights, a practical consideration for patients who already have fragmented sleep. Clinicians may consider scheduling injections on days when brief sleep disruption is least consequential.

Comparing Romosozumab to Other Anabolic Bone Agents on Sleep Profile

Teriparatide (Forteo, PTH 1-34) and abaloparatide (Tymlos, PTHrP analog) are the other FDA-approved anabolic bone agents. Neither has a formal sleep-architecture indication, but both carry different CNS profiles worth noting.

Teriparatide's prescribing information lists dizziness and leg cramps as adverse events in roughly 8% and 3% of patients respectively, both of which can fragment sleep [11]. No head-to-head polysomnographic comparison of teriparatide versus romosozumab exists in the published literature as of 2025.

Abaloparatide (Tymlos) 80 mcg daily subcutaneous was approved in 2017 based on the ACTIVE trial (N=2,463), which showed 86% reduction in vertebral fractures versus placebo at 18 months [12]. The ACTIVE trial also did not include polysomnographic endpoints. Abaloparatide's label notes dizziness (10%) and palpitations (4%), but no sleep-staging data [12].

Romosozumab's 12-month treatment ceiling and monthly dosing schedule differentiate it from daily injectables, potentially reducing cumulative injection-related sleep interruption if patients administer it at a consistent time of the monthly cycle.

Clinical Guidance for Prescribers Concerned About Sleep

The following framework synthesizes available evidence and biological plausibility for clinicians considering romosozumab in patients who report sleep concerns or carry a sleep-disorder diagnosis.

Step 1: Baseline Sleep Risk Stratification

Before initiating romosozumab, assess:

• STOP-BANG score (OSA screening; score of 3 or higher warrants further evaluation given the cardiovascular black-box warning)
• Pittsburgh Sleep Quality Index (PSQI) or Insomnia Severity Index (ISI) for baseline documentation
• Current use of sedative-hypnotics or CNS-active medications, because Wnt modulation interactions with these agents have not been studied
• Chronic pain burden related to existing vertebral fractures, since fracture-related pain is a primary driver of poor sleep in this population

Step 2: Timing the Injection

Monthly subcutaneous dosing gives flexibility. Administer the injection on a Friday or the day before a lower-responsibility workday so that any injection-site discomfort occurs when the patient can rest. Avoid co-administering calcium supplements at bedtime on injection day unless specifically required for hypocalcemia prevention, as some patients report gastrointestinal discomfort with calcium that further disrupts sleep.

Step 3: Monitor at Month 3 and Month 6

At the month-3 and month-6 visits, re-administer the PSQI or ISI. Any new-onset insomnia, excessive daytime sleepiness, or marked change in sleep quality should prompt evaluation for:

• OSA (if not previously screened)
• Hypocalcemia (serum calcium below 8.5 mg/dL, which can cause nocturnal muscle cramps and paresthesias)
• Pain flare related to atypical fracture or osteonecrosis (both rare but real)
• Unrelated causes (life stressors, new medications, menopause-related vasomotor symptoms)

Step 4: After the 12-Month Course

Romosozumab is approved for a single 12-month course. Transition therapy (typically denosumab or an oral bisphosphonate) begins at month 13 [1]. The sleep-monitoring approach does not end at month 12. Bisphosphonates are not sleep-neutral either: a 2022 analysis in the Journal of Bone and Mineral Research using UK Biobank data (N=12,467 bisphosphonate users) found a modest but statistically significant association between bisphosphonate use and self-reported poor sleep quality (OR 1.14, 95% CI 1.04 to 1.25) [13]. Continuity of sleep tracking across the treatment transition is therefore clinically warranted.

What the Evidence Gaps Mean for Patients Right Now

The honest clinical answer is that no trial has tested whether romosozumab changes polysomnographic sleep architecture. The biological pathways exist. The cardiovascular warning creates a clinically relevant reason to screen for sleep-disordered breathing before starting the drug. Functional pain relief from fracture reduction may improve sleep quality over the 12-month course, an indirect benefit that no sleep-specific endpoint has captured.

Patients prescribed romosozumab 210 mg monthly for severe postmenopausal osteoporosis should not expect a sleep medication and should not fear a sedative or stimulant effect. Any new sleep complaints emerging within the first 3 months of treatment deserve clinical evaluation rather than automatic attribution to the drug, because the postmenopausal demographic carries high baseline rates of insomnia, OSA, and restless leg syndrome independent of bone therapy [8].

The most evidence-supported statement a clinician can make today: romosozumab's 48% reduction in vertebral fractures seen in ARCH may reduce the chronic pain burden that disrupts sleep in severely affected osteoporosis patients, and this potential indirect benefit is the strongest sleep-related argument for the drug's use [2].